Affimed (AFMD) Earning Somewhat Favorable Press Coverage, Study Shows

Press coverage about Affimed (NASDAQ:AFMD) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Affimed earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.4758254335088 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Affimed (NASDAQ:AFMD) opened at $2.00 on Tuesday. The company has a quick ratio of 6.39, a current ratio of 6.43 and a debt-to-equity ratio of 0.14. Affimed has a fifty-two week low of $1.65 and a fifty-two week high of $2.95.

A number of equities analysts have issued reports on the stock. Oppenheimer reaffirmed a “hold” rating on shares of Affimed in a report on Friday, November 24th. ValuEngine downgraded shares of Affimed from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.

WARNING: This piece was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/05/affimed-afmd-earning-somewhat-favorable-press-coverage-study-shows.html.

Affimed Company Profile

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Insider Buying and Selling by Quarter for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply